TW201716059A - 新穎方法 - Google Patents

新穎方法 Download PDF

Info

Publication number
TW201716059A
TW201716059A TW105115290A TW105115290A TW201716059A TW 201716059 A TW201716059 A TW 201716059A TW 105115290 A TW105115290 A TW 105115290A TW 105115290 A TW105115290 A TW 105115290A TW 201716059 A TW201716059 A TW 201716059A
Authority
TW
Taiwan
Prior art keywords
pharmaceutically acceptable
acceptable salt
trifluoromethyl
formula
prodrug
Prior art date
Application number
TW105115290A
Other languages
English (en)
Chinese (zh)
Inventor
馬克Ｆ 佩爾蒂埃
喬治 威廉 法爾
保羅 羅伯特 馬葛克
Original Assignee
阿羅米斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 阿羅米斯公司 filed Critical 阿羅米斯公司
Publication of TW201716059A publication Critical patent/TW201716059A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/141—Esters of phosphorous acids
    • C07F9/145—Esters of phosphorous acids with hydroxyaryl compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
TW105115290A 2014-11-13 2016-05-18 新穎方法 TW201716059A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079541P 2014-11-13 2014-11-13
US201462080241P 2014-11-14 2014-11-14
PCT/US2015/060731 WO2016077787A1 (en) 2014-11-13 2015-11-13 Novel methods

Publications (1)

Publication Number Publication Date
TW201716059A true TW201716059A (zh) 2017-05-16

Family

ID=55955168

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105115290A TW201716059A (zh) 2014-11-13 2016-05-18 新穎方法

Country Status (10)

Country Link
US (1) US20180042873A1 (enExample)
EP (1) EP3218354A4 (enExample)
JP (1) JP2017535546A (enExample)
CN (1) CN107207417A (enExample)
AU (1) AU2015346076A1 (enExample)
CA (1) CA2966950A1 (enExample)
IL (1) IL252086A0 (enExample)
SG (1) SG11201703801SA (enExample)
TW (1) TW201716059A (enExample)
WO (1) WO2016077787A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
EP3062808B1 (en) 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
AU2017261828B2 (en) 2016-05-13 2023-04-13 Aeromics, Inc. Crystals
PH12022550448A1 (en) * 2019-08-23 2022-12-12 Daewoong Pharmaceutical Co Ltd Niclosamide delayed-release composition and antiviral use thereof
CN110790787B (zh) * 2019-11-12 2022-06-14 广东药科大学 一类水溶性前药、其制备方法及其作为药物的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002049632A1 (en) * 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
WO2003103658A1 (ja) * 2002-06-05 2003-12-18 株式会社医薬分子設計研究所 免疫関連プロテインキナーゼ阻害剤
US7626042B2 (en) * 2002-06-06 2009-12-01 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
EP2543249B1 (en) * 2007-02-17 2018-05-23 President and Fellows of Harvard College Compositions and method for tissue preservation
WO2009054439A1 (ja) * 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
CN104602682B (zh) * 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物

Also Published As

Publication number Publication date
EP3218354A1 (en) 2017-09-20
CA2966950A1 (en) 2016-05-19
WO2016077787A1 (en) 2016-05-19
AU2015346076A1 (en) 2017-06-15
EP3218354A4 (en) 2018-06-13
JP2017535546A (ja) 2017-11-30
US20180042873A1 (en) 2018-02-15
CN107207417A (zh) 2017-09-26
IL252086A0 (en) 2017-07-31
SG11201703801SA (en) 2017-06-29

Similar Documents

Publication Publication Date Title
JP2017535546A (ja) 新規な方法
Mendes-Braz et al. The current state of knowledge of hepatic ischemia‐reperfusion injury based on its study in experimental models
JP2017535546A5 (enExample)
AU740531B2 (en) Graft survival prolongation with porphyrins
CA3111217A1 (en) Methods of treating cytokine release syndrome
TW201325586A (zh) 移植器官植活促進劑
JP2016509050A5 (enExample)
JP2017529396A5 (enExample)
ES2363914T3 (es) Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
CN102083443B (zh) 调节肌动蛋白细胞骨架重排和细胞间间隙形成的方法
CA3092596C (en) Novel aminothiol reduction of ischemia-reperfusion-induced cell death
CA2962655C (en) A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
US20200281190A1 (en) Organ preconditioning formulation with mitochondrial elongating agents
JP6878418B2 (ja) 移植片拒絶反応の処置方法
US20180296610A1 (en) Methods for Improving Cognition and Slowing Cognitive Impairment
GB2590341A (en) Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof
JP6976577B2 (ja) ＰＰＡＲαアゴニストを含有する、肺高血圧症の予防又は治療剤
US20200316011A1 (en) Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy
US12616673B2 (en) Compounds for use in the treatment of leukemia
RU2481839C2 (ru) Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
WO2016040342A1 (en) Early lactation administration of non-steroidal anti-inflammatory drugs to increase whole-lactation milk yield
Adya Management of scleroderma
Gavrilin et al. SCREENING OF NEW CHEMOTHERAPEUTIC AGENTS TO COMBAT FISH DISEASES CAUSED BY PARASITIC DIPLOMARAGNIDAE (DIPLOMONADIDA WENYON, 1926)
EP3331519A1 (en) Abscisic acid for reducing damage to transplanted tissue
WO2017147003A1 (en) Novel macrocyclic antibiotics and uses thereof